IMMUCELL CORP /DE/ 8-K

What Happened ImmuCell Corp (ICCC) announced changes to its Board of Directors: three directors—Bryan K. Gathagan, Michael F. Brigham, and Bobbi Jo Brockmann—tendered resignations effective April 15, 2026. At a Board meeting on April 7, 2026 the Board also elected two new directors, Gilles Guillemette, DVM, and Anthony DiMarco, Ph.D., effective April 15, 2026. The company filed the Form 8‑K on April 14, 2026 and furnished a press release (Apr 13, 2026). ImmuCell also posted an investor presentation to its website consistent with its recently filed 2025 Form 10‑K.

Key Details

• Departures: Bryan K. Gathagan (declined to run for re‑election), Michael F. Brigham (retired from CEO Nov 1, 2025; director since 1999), and Bobbi Jo Brockmann (resigned as director but continues as VP of Sales & Marketing). All resignations effective April 15, 2026.
• Additions: Gilles Guillemette, DVM (30+ years in animal health; to chair new Strategy & Technology Committee and join Audit Committee) and Anthony DiMarco, Ph.D. (4 decades in biologics; to serve on Compensation, Nominations, and Strategy & Technology Committees).
• Governance note: The company stated it is not aware of any transactions with the new directors requiring disclosure under Item 404(a) of Regulation S‑K.
• Investor materials: An investor presentation dated April 13, 2026 was posted that aligns with the company’s March 30, 2026 Form 10‑K.

Why It Matters Board turnover and the addition of two directors with deep animal‑health and biologics experience may influence ImmuCell’s strategic oversight, R&D and manufacturing guidance, and governance priorities—areas important to investors tracking company direction after its CEO transition. The filing confirms orderly succession steps (effective April 15, 2026) and supplements public materials with an updated investor presentation for shareholders to review.